ACADIA to Host Conference Call and Webcast on Monday, November 7,2016, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Nov. 1, 2016—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system disorders,today announced that it will report its unaudited financial results forthe third quarter ended September 30, 2016 on Monday, November 7, 2016,after the U.S. financial markets close. ACADIA's management will host aconference call and webcast on Monday, November 7, 2016, at 5:00 p.m.Eastern Time to discuss ACADIA’s financial results and operations.
The conference call may be accessed by dialing 844-821-1109 forparticipants in the United States or Canada and 830-865-2550 forinternational callers (reference passcode 6571523). A telephone replayof the conference call may be accessed through November 21, 2016 bydialing 855-859-2056 for callers in the United States or Canada and404-537-3406 for international callers (reference passcode 6571523). Theconference call also will be webcast live on ACADIA’s website, www.acadia-pharm.comunder the investors section and will be archived there until November21, 2016.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines that address unmet medicalneeds in central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA’sdrug discovery and development programs, and the benefits to be derivedfrom NUPLAZID® (pimavanserin) and ACADIA’s productcandidates. These statements are only predictions based on currentinformation and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingthe risks and uncertainties inherent in drug discovery, development,approval and commercialization, and in collaborations with others, andthe fact that past results of clinical trials may not be indicative offuture trial results. For a discussion of these and other factors,please refer to ACADIA’s annual report on Form 10-K for the year endedDecember 31, 2015 as well as ACADIA’s subsequent filings with theSecurities and Exchange Commission. You are cautioned not to place unduereliance on these forward-looking statements, which speak only as of thedate hereof. This caution is made under the safe harbor provisions ofthe Private Securities Litigation Reform Act of 1995. Allforward-looking statements are qualified in their entirety by thiscautionary statement and ACADIA undertakes no obligation to revise orupdate this press release to reflect events or circumstances after thedate hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, InvestorRelations
(858) 558-2871
ir@acadia-pharm.com